T&R Biofab Co. Ltd (KQ:246710) — Market Cap & Net Worth
Market Cap & Net Worth: T&R Biofab Co. Ltd (246710)
T&R Biofab Co. Ltd (KQ:246710) has a market capitalization of $53.24 Million (₩78.55 Billion) as of August 16, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #21730 globally and #1318 in its home market, demonstrating a -0.58% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying T&R Biofab Co. Ltd's stock price ₩2575.00 by its total outstanding shares 30506586 (30.51 Million). See 246710 equity to assets ratio to understand what proportion of total assets are financed by equity.
T&R Biofab Co. Ltd Market Cap History: 2018 to 2026
T&R Biofab Co. Ltd's market capitalization history from 2018 to 2026. Data shows change from $92.10 Million to $53.24 Million (-10.86% CAGR). Also see balance sheet size of T&R Biofab Co. Ltd for a full breakdown of the balance sheet.
Index Memberships
T&R Biofab Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$238.91 Billion | 0.02% | #620 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$238.91 Billion | 0.02% | #620 of 1384 |
Weight: T&R Biofab Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
T&R Biofab Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how T&R Biofab Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest T&R Biofab Co. Ltd stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.02x
T&R Biofab Co. Ltd's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $92.10 Million | $974.32 Million | -$4.69 Billion | 0.09x | N/A |
| 2019 | $103.37 Million | $1.29 Billion | -$6.25 Billion | 0.08x | N/A |
| 2020 | $174.18 Million | $6.81 Billion | -$5.60 Billion | 0.03x | N/A |
| 2021 | $518.91 Million | $3.23 Billion | -$11.08 Billion | 0.16x | N/A |
| 2022 | $236.72 Million | $5.75 Billion | -$10.34 Billion | 0.04x | N/A |
| 2023 | $184.62 Million | $5.20 Billion | -$13.42 Billion | 0.04x | N/A |
| 2024 | $89.62 Million | $4.87 Billion | -$7.68 Billion | 0.02x | N/A |
Competitor Companies of 246710 by Market Capitalization
Companies near T&R Biofab Co. Ltd in the global market cap rankings as of August 16, 2026. Also see T&R Biofab Co. Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Key companies related to T&R Biofab Co. Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #107 globally with a market cap of $193.45 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #183 globally with a market cap of $129.81 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #237 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #240 globally with a market cap of $103.60 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #107 | Abbott Laboratories | NYSE:ABT | $193.45 Billion | $111.25 |
| #183 | Stryker Corporation | NYSE:SYK | $129.81 Billion | $339.21 |
| #237 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #240 | Medtronic PLC | NYSE:MDT | $103.60 Billion | $91.27 |
T&R Biofab Co. Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, T&R Biofab Co. Ltd's market cap moved from $92.10 Million to $ 53.24 Million, with a yearly change of -10.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩53.24 Million | -34.14% |
| 2025 | ₩80.83 Million | -9.80% |
| 2024 | ₩89.62 Million | -51.46% |
| 2023 | ₩184.62 Million | -22.01% |
| 2022 | ₩236.72 Million | -54.38% |
| 2021 | ₩518.91 Million | +197.92% |
| 2020 | ₩174.18 Million | +68.50% |
| 2019 | ₩103.37 Million | +12.23% |
| 2018 | ₩92.10 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 15th, 2026 the market cap of T&R Biofab Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $53.24 Million USD |
| MoneyControl | $53.24 Million USD |
| MarketWatch | $53.24 Million USD |
| marketcap.company | $53.24 Million USD |
| Reuters | $53.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About T&R Biofab Co. Ltd
T&R Biofab Co., Ltd. develops and commercializes various regenerative medical technologies. It offers 3D-printed medical devices; and bio-surgical solutions, which includes wound dressing and acellular dermal matrix, as well as biomaterials and biopharmaceuticals. The company was founded in 2013 and is based in Siheung-si, South Korea.